These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 19220493)

  • 21. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?
    Fontas E; van Leth F; Sabin CA; Friis-Møller N; Rickenbach M; d'Arminio Monforte A; Kirk O; Dupon M; Morfeldt L; Mateu S; Petoumenos K; El-Sadr W; de Wit S; Lundgren JD; Pradier C; Reiss P;
    J Infect Dis; 2004 Mar; 189(6):1056-74. PubMed ID: 14999610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term prognostic value of LDL-C, HDL-C, lp(a) and TG levels on cardiovascular disease incidence, by body weight status, dietary habits and lipid-lowering treatment: the ATTICA epidemiological cohort study (2002-2012).
    Georgoulis M; Chrysohoou C; Georgousopoulou E; Damigou E; Skoumas I; Pitsavos C; Panagiotakos D
    Lipids Health Dis; 2022 Dec; 21(1):141. PubMed ID: 36529737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study.
    Jao J; Yu W; Patel K; Miller TL; Karalius B; Geffner ME; DiMeglio LA; Mirza A; Chen JS; Silio M; McFarland EJ; Van Dyke RB; Jacobson D;
    HIV Med; 2018 Mar; 19(3):175-183. PubMed ID: 29159965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations.
    Sinxadi PZ; McIlleron HM; Dave JA; Smith PJ; Levitt NS; Haas DW; Maartens G
    Medicine (Baltimore); 2016 Jan; 95(2):e2385. PubMed ID: 26765416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.
    ; Ratsela A; Polis M; Dhlomo S; Emery S; Grandits G; Khabo P; Khanyile T; Komati S; Neaton JD; Naidoo LC; Magongoa D; Qolohle D
    J Infect Dis; 2010 Nov; 202(10):1529-37. PubMed ID: 20942650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA).
    Taramasso L; Tatarelli P; Ricci E; Madeddu G; Menzaghi B; Squillace N; De Socio GV; Martinelli C; Gulminetti R; Maggi P; Orofino G; Vichi F; Di Biagio A; Bonfanti P;
    BMC Infect Dis; 2018 Jul; 18(1):357. PubMed ID: 30064371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women.
    Arsenault BJ; Rana JS; Stroes ES; Després JP; Shah PK; Kastelein JJ; Wareham NJ; Boekholdt SM; Khaw KT
    J Am Coll Cardiol; 2009 Dec; 55(1):35-41. PubMed ID: 20117361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipid metabolism and lipodystrophy in HIV-1-infected patients: the role played by nonnucleoside reverse transcriptase inhibitors.
    Sension M; Deckx H
    AIDS Rev; 2015; 17(1):21-36. PubMed ID: 25472015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The analysis of the lipid levels in patients with coronary artery disease after percutaneous coronary intervention: a one-year follow-up observational study.
    Qiu W; Chen J; Huang X; Guo J
    Lipids Health Dis; 2020 Jul; 19(1):163. PubMed ID: 32631347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increase in standard cholesterol and large HDL particle subclasses in antiretroviral-naïve patients prescribed efavirenz compared to atazanavir/ritonavir.
    Gotti D; Cesana BM; Albini L; Calabresi A; Izzo I; Focà E; Motta D; Bellagamba R; Fezza R; Narciso P; Sighinolfi L; Maggi P; Brianese N; Quiros-Roldan E; Guaraldi G; Torti C
    HIV Clin Trials; 2012; 13(5):245-55. PubMed ID: 23134625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.
    Young J; Weber R; Rickenbach M; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
    Antivir Ther; 2005; 10(5):585-91. PubMed ID: 16152752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
    van Leth F; Phanuphak P; Stroes E; Gazzard B; Cahn P; Raffi F; Wood R; Bloch M; Katlama C; Kastelein JJ; Schechter M; Murphy RL; Horban A; Hall DB; Lange JM; Reiss P
    PLoS Med; 2004 Oct; 1(1):e19. PubMed ID: 15526045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Secular Trends in Lipid Profiles in Korean Adults Based on the 2005-2015 KNHANES.
    Kwon YJ; Lee JW; Kang HT
    Int J Environ Res Public Health; 2019 Jul; 16(14):. PubMed ID: 31319575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term effectiveness of first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in Ghana.
    Sarfo FS; Sarfo MA; Kasim A; Phillips R; Booth M; Chadwick D
    J Antimicrob Chemother; 2014 Jan; 69(1):254-61. PubMed ID: 24003181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The triglyceride-high-density lipoprotein axis: an important target of therapy?
    Szapary PO; Rader DJ
    Am Heart J; 2004 Aug; 148(2):211-21. PubMed ID: 15308990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipid profile changes in Thai HIV and tuberculosis co-infected patients receiving non-nucleoside reverse transcriptase inhibitors-based antiretroviral therapy.
    Mankhatitham W; Luaengniyomkul A; Manosuthi W
    J Med Assoc Thai; 2012 Feb; 95(2):163-9. PubMed ID: 22435244
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.
    Shey MS; Kongnyuy EJ; Alobwede SM; Wiysonge CS
    Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD005481. PubMed ID: 23543540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Open-label randomized multicenter selection study of once daily antiretroviral treatment regimen comparing ritonavir-boosted atazanavir to efavirenz with fixed-dose abacavir and lamivudine.
    Honda M; Ishisaka M; Ishizuka N; Kimura S; Oka S;
    Intern Med; 2011; 50(7):699-705. PubMed ID: 21467701
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection.
    Wand H; Calmy A; Carey DL; Samaras K; Carr A; Law MG; Cooper DA; Emery S;
    AIDS; 2007 Nov; 21(18):2445-53. PubMed ID: 18025881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.